SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEFM14A - Definitive proxy statement relating to merger or acquisition:
SEC Accession No. 0001193125-24-153666
Filing Date
2024-06-04
Accepted
2024-06-04 08:00:29
Documents
10

Document Format Files

Seq Description Document Type Size
1 DEFM14A d787069ddefm14a.htm DEFM14A 2713006
2 GRAPHIC g787069g01t01.jpg GRAPHIC 29366
3 GRAPHIC g787069g14w57.jpg GRAPHIC 62234
4 GRAPHIC g787069g24g24.jpg GRAPHIC 39808
5 GRAPHIC g787069g32g32.jpg GRAPHIC 231942
6 GRAPHIC g787069g33g33.jpg GRAPHIC 128318
7 GRAPHIC g787069g40u42.jpg GRAPHIC 20037
8 GRAPHIC g787069g65m78.jpg GRAPHIC 64312
9 GRAPHIC g787069g67b93.jpg GRAPHIC 38130
10 GRAPHIC g787069g93f08.jpg GRAPHIC 46409
  Complete submission text file 0001193125-24-153666.txt   3605272
Mailing Address 2801 CENTERVILLE ROAD 1ST FLOOR PMB #117 WILMINGTON DE 19808
Business Address 2801 CENTERVILLE ROAD 1ST FLOOR PMB #117 WILMINGTON DE 19808 877-354-3689
Eliem Therapeutics, Inc. (Filer) CIK: 0001768446 (see all company filings)

IRS No.: 832273741 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEFM14A | Act: 34 | File No.: 001-40708 | Film No.: 241016104
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)